Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2018

Open Access 01-12-2018 | Primary research

RelB plays an oncogenic role and conveys chemo-resistance to DLD-1 colon cancer cells

Authors: Xiaojun Zhou, Zhili Shan, Hengying Yang, Jingjing Xu, Wenjing Li, Feng Guo

Published in: Cancer Cell International | Issue 1/2018

Login to get access

Abstract

Background

Nuclear transcription factor kappa B (NF-κB) subunits exhibit crucial roles in tumorigenesis and chemo-sensitivity. Recent studies suggest that RelB, the key subunit of the alternative NF-κB pathway, plays a critical role in the progression of diverse human malignancies. However, the significance of RelB in colorectal cancer (CRC) remains unclear. Here, we systematically explored the functions of the alternative NF-κB subunit RelB in colon cancer cells and its underlying mechanism.

Methods

Stably transfected RelB-shRNA DLD-1 cells were established using Lipofectamine 2000. NF-κB DNA-binding capability was quantified using an ELISA-based NF-κB activity assay. Cell growth was monitored by an x-Celligence system. Cell proliferation was analyzed by a CCK-8 and a Brdu proliferation assay. Response to 5-FU was assessed by an x-Celligence system. Cell apoptosis and cell cycle was detected using flow cytometry analyses. Cell migration and invasion abilities were detected by an x-Celligence system, Transwell inserts, and wound-healing assays. RelB expression and its clinical significance were analyzed using the CRC tissue microarray. The expression of NF-κB signaling subunits, AKT/mTOR signaling molecules, cell cycle related proteins, MMP2, MMP9, and Integrin β-1 were measured by Western blotting analyses.

Results

The RelB-silencing inhibited cell growth of DLD-1 cells. The RelB-silencing exerted the anti-proliferative by downregulation of AKT/mTOR signaling. The RelB-silencing caused G0–G1 cell cycle arrested likely due to decreasing the expression of Cyclin D1 and CDK4, concomitant with increased expression of p27Kip1. The RelB-silencing enhanced cytotoxic effect of 5-FU and induced cell accumulation in S-phase. The RelB-silencing impaired the migration and invasion potential of DLD-1 cells, which was related to downregulation of MMP2, MMP9, and Integrin β-1. Importantly, the RelB expression was correlated with depth of tumor invasion, lymph node metastasis, metastasis stage, and pTNM stage. High-RelB expression was significantly correlated with poor overall survival in CRC patients.

Conclusion

Our studies here provided evidence that RelB plays an oncogenic role and conveys chemo-resistance to 5-FU. RelB can be considered as an independent indicator of prognosis in CRC.
Literature
1.
Siegel R, Miller K, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRef
2.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.PubMedCrossRef
3.
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.PubMedCrossRef
4.
Tsilimigras D, Ntanasis-Stathopoulos I, Bagante F, Moris D, Cloyd J, Spartalis E, Pawlik T. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: a systematic review of the current evidence. Surg Oncol. 2018;27(2):280–8.PubMedCrossRef
5.
Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell. 1986;47(6):921–8.PubMedCrossRef
6.
7.
Colombo F, Zambrano S, Agresti A. NF-κB, the importance of being dynamic: role and insights in cancer. Biomedicines. 2018;6(2):45–58.PubMedCentralCrossRef
8.
9.
10.
Patel M, Horgan PG, McMillan DC, Edwards J. NF-kappaB pathways in the development and progression of colorectal cancer. Transl Res. 2018;197:43–56.PubMedCrossRef
11.
Porta C, Ippolito A, Consonni F, Carraro L, Celesti G, Correale C, Grizzi F, Pasqualini F, Tartari S, Rinaldi M, et al. Protumor steering of cancer inflammation by p50 NF-κB enhances colorectal cancer progression. Cancer Immunol Res. 2018;6(5):578–93.PubMedCrossRef
12.
Greten F, Eckmann L, Greten T, Park J, Li Z, Egan L, Kagnoff M, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 2004;118(3):285–96.PubMedCrossRef
13.
Qin M, Liu S, Li A, Xu C, Tan L, Huang J, Liu S. NIK- and IKKβ-binding protein promotes colon cancer metastasis by activating the classical NF-κB pathway and MMPs. Tumour Biol. 2016;37(5):5979–90.PubMedCrossRef
14.
Anthony N, Baiget J, Berretta G, Boyd M, Breen D, Edwards J, Gamble C, Gray A, Harvey A, Hatziieremia S, et al. Inhibitory kappa B kinase α (IKKα) inhibitors that recapitulate their selectivity in cells against isoform-related biomarkers. J Med Chem. 2017;60(16):7043–66.PubMedPubMedCentralCrossRef
15.
Baud V, Collares D. Post-translational modifications of RelB NF-kappaB subunit and associated functions. Cells. 2016;5(2):22–32.PubMedCentralCrossRef
16.
Grinberg-Bleyer Y, Caron R, Seeley J, De Silva N, Schindler C, Hayden M, Klein U, Ghosh S. The alternative NF-κB pathway in regulatory T cell homeostasis and suppressive function. J Immunol. 2018;200(7):2362–71.PubMedCrossRef
17.
Weih F, Carrasco D, Durham S, Barton D, Rizzo C, Ryseck R, Lira S, Bravo R. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kappa B/Rel family. Cell. 1995;80(2):331–40.PubMedCrossRef
18.
Guo F, Tanzer S, Busslinger M, Weih F. Lack of nuclear factor-kappa B2/p100 causes a RelB-dependent block in early B lymphopoiesis. Blood. 2008;112(3):551–9.PubMedCrossRef
19.
Shen M, Duan X, Zhou P, Zhou W, Wu X, Xu S, Chen Y, Tao Z. Lymphotoxin β receptor activation promotes bladder cancer in a nuclear factor-κB-dependent manner. Mol Med Rep. 2015;11(2):783–90.PubMedCrossRef
20.
Lessard L, Bégin L, Gleave M, Mes-Masson A, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer. 2005;93(9):1019–23.PubMedPubMedCentralCrossRef
21.
Wei X, Xu Y, Xu F, Chaiswing L, Schnell D, Noel T, Wang C, Chen J, St Clair D, St Clair W. RelB expression determines the differential effects of ascorbic acid in normal and cancer cells. Cancer Res. 2017;77(6):1345–56.PubMedPubMedCentralCrossRef
22.
Wang J, Yi S, Zhou J, Zhang Y, Guo F. The NF-κB subunit RelB regulates the migration and invasion abilities and the radio-sensitivity of prostate cancer cells. Int J Oncol. 2016;49(1):381–92.PubMedCrossRef
23.
24.
Qin H, Zhou J, Zhou P, Xu J, Tang Z, Ma H, Guo F. Prognostic significance of RelB overexpression in non-small cell lung cancer patients. Thorac Cancer. 2016;7(4):415–21.PubMedPubMedCentralCrossRef
25.
Qin H, Zhou J, Xu J, Cheng L, Tang Z, Ma H, Guo F. The nuclear transcription factor RelB functions as an oncogene in human lung adenocarcinoma SPC-A1 cells. Cancer Cell Int. 2018;18(1):88–101.PubMedPubMedCentralCrossRef
26.
Tejpar S, Yan P, Piessevaux H, Dietrich D, Brauchli P, Klingbiel D, Fiocca R, Delorenzi M, Bosman F, Roth A. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: results of the PETACC-3 trial. Eur J Cancer. 2018;99:66–77.PubMedCrossRef
27.
Vaiopoulos A, Papachroni K, Papavassiliou A. Colon carcinogenesis: learning from NF-kappaB and AP-1. Int J Biochem Cell Biol. 2010;42(7):1061–5.PubMedCrossRef
28.
29.
Zhu HC, Qiu T, Dan C, Liu XH, Hu CH. Blockage of RelB expression by gene silencing enhances the radiosensitivity of androgen independent prostate cancer cells. Mol Med Rep. 2015;11(2):1167–73.PubMedCrossRef
30.
Mineva N, Wang X, Yang S, Ying H, Xiao Z, Holick M, Sonenshein G. Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation. J Cell Physiol. 2009;220(3):593–9.PubMedPubMedCentralCrossRef
31.
Giopanou I, Lilis I, Papaleonidopoulos V, Marazioti A, Spella M, Vreka M, Papadaki H, Stathopoulos G. Comprehensive evaluation of nuclear factor-κΒ expression patterns in non-small cell lung cancer. PLoS ONE. 2015;10(7):e0132527.PubMedPubMedCentralCrossRef
32.
Ge QL, Liu SH, Ai ZH, Tao MF, Ma L, Wen SY, Dai M, Liu F, Liu HS, Jiang RZ, et al. RelB/NF-kappaB links cell cycle transition and apoptosis to endometrioid adenocarcinoma tumorigenesis. Cell Death Dis. 2016;7(10):e2402.PubMedPubMedCentralCrossRef
33.
34.
Holley A, Xu Y, St Clair D, St Clair W. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Ann N Y Acad Sci. 2010;1201:129–36.PubMedPubMedCentralCrossRef
35.
Xu J, Zhou P, Wang W, Sun A, Guo F. RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow. J Mol Med. 2014;92(1):77–92.PubMedCrossRef
36.
Demchenko YN, Glebov OK, Zingone A, Keats JJ, Bergsagel PL, Kuehl WM. Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood. 2010;115(17):3541–52.PubMedPubMedCentralCrossRef
37.
Vallabhapurapu S, Noothi S, Pullum D, Lawrie C, Pallapati R, Potluri V, Kuntzen C, Khan S, Plas D, Orlowski R, et al. Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth. Nat Commun. 2015;6:8428–42.PubMedCrossRef
38.
Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell R. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev. 2001;12(1):73–90.PubMedCrossRef
39.
40.
Chen L, She X, Wang T, He L, Shigdar S, Duan W, Kong L. Overcoming acquired drug resistance in colorectal cancer cells by targeted delivery of 5-FU with EGF grafted hollow mesoporous silica nanoparticles. Nanoscale. 2015;7(33):14080–92.PubMedCrossRef
41.
Lagadec P, Griessinger E, Nawrot M, Fenouille N, Colosetti P, Imbert V, Mari M, Hofman P, Czerucka D, Rousseau D, et al. Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer. 2008;98(2):335–44.PubMedPubMedCentralCrossRef
42.
Wang Z, Zhao X, Wang W, Liu Y, Li Y, Gao J, Wang C, Zhou M, Liu R, Xu G, et al. ZBTB7 evokes 5-fluorouracil resistance in colorectal cancer through the NF-κB signaling pathway. Int J Oncol. 2018;53(5):2102–10.PubMed
43.
Fabre C, Mimura N, Bobb K, Kong S, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, et al. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012;18(17):4669–81.PubMedPubMedCentralCrossRef
44.
Choi J, Yoon J, Won Y, Park B, Lee Y. Chloroquine enhances the chemotherapeutic activity of 5-fluorouracil in a colon cancer cell line via cell cycle alteration. APMIS. 2012;120(7):597–604.PubMedCrossRef
45.
Meiyanto E, Septisetyani EP, Larasati YA, Kawaichi M. Curcumin analog pentagamavunon-1 (PGV-1) sensitizes Widr cells to 5-fluorouracil through inhibition of NF-kappaB activation. Asian Pac J Cancer Prev. 2018;19(1):49–56.PubMedPubMedCentral
46.
Qin A, Yu Q, Gao Y, Tan J, Huang H, Qiao Z, Qian W. Inhibition of STAT3/cyclinD1 pathway promotes chemotherapeutic sensitivity of colorectal caner. Biochem Biophys Res Commun. 2015;457(4):681–7.PubMedCrossRef
47.
Sun Q, Zhou C, Ma R, Guo Q, Huang H, Hao J, Liu H, Shi R, Liu B. Prognostic value of increased integrin-beta 1 expression in solid cancers: a meta-analysis. Onco Targets Ther. 2018;11:1787–99.PubMedPubMedCentralCrossRef
48.
Laudato S, Patil N, Abba M, Leupold J, Benner A, Gaiser T, Marx A, Allgayer H. P53-induced miR-30e-5p inhibits colorectal cancer invasion and metastasis by targeting ITGA6 and ITGB1. Int J Cancer. 2017;141(9):1879–90.PubMedCrossRef
49.
Langan R, Mullinax J, Ray S, Raiji M, Schaub N, Xin H, Koizumi T, Steinberg S, Anderson A, Wiegand G, et al. A pilot study assessing the potential role of non-CD133 colorectal cancer stem cells as biomarkers. J Cancer. 2012;3:231–40.PubMedPubMedCentralCrossRef
50.
Liu Q, Gao X, Chang W, Gong H, Fu C, Zhang W, Cao G. Expression of ITGB1 predicts prognosis in colorectal cancer: a large prospective study based on tissue microarray. Int J Clin Exp Pathol. 2015;8(10):12802–10.PubMedPubMedCentral
51.
Vinnakota K, Zhang Y, Selvanesan B, Topi G, Salim T, Sand-Dejmek J, Jönsson G, Sjölander A. M2-like macrophages induce colon cancer cell invasion via matrix metalloproteinases. J Cell Physiol. 2017;232(12):3468–80.PubMedCrossRef
52.
Collins H, Morris T, Watson S. Spectrum of matrix metalloproteinase expression in primary and metastatic colon cancer: relationship to the tissue inhibitors of metalloproteinases and membrane type-1-matrix metalloproteinase. Br J Cancer. 2001;84(12):1664–70.PubMedPubMedCentralCrossRef
53.
Cherry E, Lee D, Jung J, Sitcheran R. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-κB-inducing kinase (NIK) and noncanonical NF-κB signaling. Mol Cancer. 2015;14(1):9–21.PubMedPubMedCentralCrossRef
54.
Shen F, Guo Q, Hu Q, Zeng A, Wu W, Yan W, You Y. RelB, a good prognosis predictor, links cell-cycle and migration to glioma tumorigenesis. Oncol Lett. 2018;15(4):4404–10.PubMedPubMedCentral
55.
Tong W, Wang Q, Sun D, Suo J. Curcumin suppresses colon cancer cell invasion via AMPK-induced inhibition of NF-κB, uPA activator and MMP9. Oncol Lett. 2016;12(5):4139–46.PubMedPubMedCentralCrossRef
Metadata
Title
RelB plays an oncogenic role and conveys chemo-resistance to DLD-1 colon cancer cells
Authors
Xiaojun Zhou
Zhili Shan
Hengying Yang
Jingjing Xu
Wenjing Li
Feng Guo
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2018
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-018-0677-x

Other articles of this Issue 1/2018

Cancer Cell International 1/2018 Go to the issue

Primary Research

Whole exome sequencing reveals novel somatic alterations in neuroblastoma patients with chemotherapy

Primary Research

MiR-544 promotes immune escape through downregulation of NCR1/NKp46 via targeting RUNX3 in liver cancer

Primary Research

Identification of four differentially methylated genes as prognostic signatures for stage I lung adenocarcinoma

Primary research

The role of bile acids in cellular invasiveness of gastric cancer

Primary Research

Effects of secreted frizzled-related protein 1 on proliferation, migration, invasion, and apoptosis of colorectal cancer cells

Primary research

SKA3 promotes cell proliferation and migration in cervical cancer by activating the PI3K/Akt signaling pathway
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits